Niagen Bioscience (NASDAQ:NAGE) Lowered to Buy Rating by Wall Street Zen

Key Points

• Niagen Bioscience's stock rating was downgraded from "strong-buy" to "buy" by Wall Street Zen in a recent report.
• The company's stock has seen changes in price targets from various analysts, with Roth Capital raising its target from $10.00 to $23.00.
• Niagen Bioscience reported earnings surpassing analyst expectations, with a quarterly EPS of $0.04 and revenue of $31.12 million.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) was downgraded by analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a research report issued on Tuesday.

A number of other equities analysts also recently issued reports on NAGE. Canaccord Genuity Group upped their price target on Niagen Bioscience from $13.00 to $16.00 and gave the stock a "buy" rating in a research report on Tuesday, June 10th. HC Wainwright upped their price target on Niagen Bioscience from $11.00 to $12.00 and gave the stock a "buy" rating in a research report on Monday, August 11th. Finally, Roth Capital reaffirmed a "buy" rating and set a $23.00 price target (up from $10.00) on shares of Niagen Bioscience in a research report on Friday, June 6th. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $13.42.

Niagen Bioscience Stock Up 0.4%

Shares of NASDAQ:NAGE opened at $9.45 on Tuesday. The company has a market capitalization of $753.64 million, a price-to-earnings ratio of 45.00 and a beta of 2.22. Niagen Bioscience has a 52 week low of $3.16 and a 52 week high of $14.69. The firm has a 50 day moving average of $10.27 and a 200 day moving average of $8.93.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.02 by $0.02. The business had revenue of $31.12 million for the quarter, compared to the consensus estimate of $28.55 million. Niagen Bioscience had a return on equity of 23.12% and a net margin of 15.24%.

Hedge Funds Weigh In On Niagen Bioscience

Hedge funds have recently made changes to their positions in the company. State of Wyoming acquired a new position in shares of Niagen Bioscience in the 4th quarter valued at $39,000. Mercer Global Advisors Inc. ADV acquired a new position in shares of Niagen Bioscience in the 4th quarter valued at $53,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of Niagen Bioscience in the 4th quarter valued at $67,000. ProShare Advisors LLC acquired a new position in shares of Niagen Bioscience in the 4th quarter valued at $74,000. Finally, Sherbrooke Park Advisers LLC acquired a new position in shares of Niagen Bioscience in the 4th quarter valued at $94,000. 15.41% of the stock is owned by institutional investors and hedge funds.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.